In-Silico Search Analysis of Potential Inhibitors for 3-Chymotrypsin-Like Protease Of Sars-Cov-2 (Covid-19)

Nasimah Rahim[1], Siti Zalita Talib[2], Nur Ainun Mokhtar[1], Nurulbahiyah Ahmad Khairudin[1],*, Ragheed Hussam Yousif[3]

[1]Malaysia-Japan International Institute of Technology, Universiti Teknologi Malaysia, Jalan Sultan Yahya Petra, 54100, Kuala Lumpur
[2]Pusat Pengurusan Makmal Universiti, Universiti Teknologi Malaysia, Jalan Sultan Yahya Petra, 54100, Kuala Lumpur
[3]Al-Farahidi University, College of Medical Technology, Baghdad, Iraq

* Correspondence: r-bahiah@utm.my
https://doi.org/10.37934/jrnn.4.1.4956

ABSTRACT

In this study, three commercial drugs, Imatinib, Nilotinib and Dexamethasone were docked against 3 Chymotrypsin-like Protease or the 3CLPRO of the Severe Acute Respiratory Syndrome (SARS-CoV-2) of coronavirus COVID-19 using the program Auto dock Vina. The objective of this study is to investigate the effectiveness of the three commercial drugs against the protein 3CLPRO. The protein and the ligands were downloaded from the Protein Data Bank and Pub Chem, respectively. The docked conformations were analysed in terms of the molecular interactions such as hydrogen bonds and hydrophobic interactions. The best drug with the lowest binding energy was Nilotinib with -9.5 kcal/mol followed by Imatinib -9.1 kcal/mol.

Keywords:
Covid-19; molecular docking; 3CLPRO;
Nilotinib; Imatinib

1. Introduction

Covid-19 is a disease that is impacting a large number of people worldwide. This disease is believed to have arisen from a human encapsulated ribonucleic acid (RNA) virus that is highly contagious and spreading rapidly [1-3] in the months following the Wuhan wet market incident, where the virus was believed to be passing from animals to humans. Novel SARS-CoV-2 virus shares many of the same characteristics as beta coronaviruses [4] and seems to be are directly related to SARS-CoV with a significant genomic similarity of approximately greater than 79 percent. All of these CoVs are members of the Coronaviridae family, which is characterized by a positive-sense single-

stranded RNA genome. This virus is composed of crown-shaped peplomers with a diameter of 80-160 nm, with only single-strand, and is around 30 kilo meters in length [5]. It has a positive polarity RNA molecule with a 5' cap and a 3' Poly-A tail. The SARS-CoV-2 spike protein interacts on its surface with the cellular receptor ACE2 (angiotensin-converting enzyme 2), which is extensively expressed in a variety of cell types in human tissues as described by [6]. The genomic RNA is composed of two polyprotein templates including: pp1a and pp1ab for direct translation. Upon internalization into the cell, they both carry a large number of non-structural proteins (nsPs), such as 3 chymotrypsin-like protease (3CLPRO) or main protease (MPRO)-nsP5 which are the main protease of COVID-19. Hence, the main protease is a significant and desirable therapeutic target for inhibiting the synthesis of non-structural viral proteins and thus impeding the virus life cycle reproduction. According to a study conducted by [7], 3CLPRO is an appealing choice for the production and implementation of improved antiviral drugs against SARS and other coronaviruses due to its functional significance in the virus replication and maturation. Zhou and colleagues mentioned that no human protease with similar cleavage specificity is known to inhibit the toxic agents invading the cell caused by blocking the main viral protease [8]. The coronavirus has induced numerous health and economic problems, including deaths and widespread job loss for two years now. As of today, no known drug or antiviral that is available to cure the Covid-19 infection. Nonetheless, a small number of broad-spectrum antiviral agents have been studied in clinical studies. Thus, this study emphasized molecular docking methods to be implemented using Auto dock Vina to investigate the effectiveness of three different commercial drugs against the protein 3CLPRO. Previous molecular docking studies have revealed a few potential ligands or commercial drugs that could act as potentials anti-Sars-Cov-2 agents [9,10,11].

2. Materials and Methods

This study involving several important steps such as receptor preparation, ligand preparation and identification and finally the docking simulation as shown in Figure 1. Software such as Auto dock tools, Autodock Vina [12] and LigPlot [13] were used in this research.


Figure 1: Flowchart of the Molecular Docking Simulations

The three-dimensional structural of 3CLPRO was retrieved from the RCSB database (PDB ID: 6LU7) (https://www.rcsb.org/) [14]. Kollman charges were added to the protein receptor. The structures of three ligands, Imatinib, Nilotinib and Dexamethasone were obtained in from the Pub Chem database (https://pubchem.ncbi.nlm.nih.gov/) [15].The center grid box for all the three ligands were set to (-45.924, -29.680, 28.571). The hydrogen bonds and hydrophobic interactions of the docked conformations were analysed using LigPlot.

3. Results and Discussion

3.1 Binding Energy of Docked Conformation

Table 1 shows the 9 top docked conformations between 3CLPRO- Imatinib, 3CLPRO-Nilotinib and 3CLPRO- Dexamethasone. It was found that the lowest binding for 3CLPRO – Imatinib = 9.1 kcal/mol, 3CLPRO – Nilotinib = 9.5 kcal/mol and 3CLPRO – Dexamethasone = 7.5 kcal/mol as shown in Figure 2, Figure 3 and Figure 4.

Table 1: Binding energy (kcal/mol) of docked conformations

| Mode	$3CL^{PRO}$ – Imatinib (kcal/mol)	$3CL^{PRO}$ – Nilotinib (kcal/mol)	CL^{PRO} –Dexamethasone (kcal/mol)
1	-9.1	-9.5	-7.5
2	-9.1	-9.5	-7.2
3	-9.0	-9.5	-7.2
4	-8.9	-9.4	-7.1
5	-8.9	-9.4	-7.1
6	-8.8	-9.3	-7.0
7	-8.8	-9.3	-7.0
8	-8.8	-9.2	-6.9
9	-8.7	-9.1	-6.9

Figure 2: Docked complex of 3CLPRO – Imatinib

Figure 3: Docked Complex of 3CLPRO – Nilotinib

Figure 4: Docked Complex of 3CLPRO – Dexamethasone

3.2 Molecular Interactions of the Docked Conformations

The hydrogen bonding interaction of 3CLPRO – Imatinib, 3CLPRO – Nilotinib and 3CLPRO – Dexamethasone were represented by the green dotted line as shown in Figure 5, Figure 6 and Figure 7. There is only 1 hydrogen bonding found for 3CLPRO – Imatinib which connects the residue Ser123 to the ligand. The hydrogen bond distance was found to be 3.16 Å. For 3CLPRO – Nilotinib, there is zero hydrogen bonds which means that all of the interactions are enforced by the hydrophobic bonding. The largest number of hydrogen bonds were found to occur in 3CLPRO – Dexamethasone. Two hydrogen bonds were formed between the residue Thr26 and the ligand with the distance of 2.08 Å and 3.13 Å. There were also hydrophobic interactions formed between the surrounding residues and the ligand as depicted in the figure.

Figure 5: The molecular interactions involved in 3CLPRO – Imatinib bonding

Figure 6: The molecular interactions involved in 3CLPRO – Nilotinib bonding

Figure 7: The molecular interactions involved in 3CLPRO – Dexamethasone bonding

Previous papers have reported similar molecular docking studies using Imatinib, Nilotinib and Dexamethasone with 3CLPRO and their binding energies were summarized in Table 2 [16]. The binding affinity were -8.9, -9.2 and -7.4 kcal/mol, respectively. These values were compared with the current obtained values -9.1, -9.5 and -7.5 Kcal/mol, respectively and the differences could be considered minimal as shown in Table 2.

Table 2: Energy binding for Imatinib, Nilotinib and Dexamethasone with 3CLPRO

Docked Complex	Previous Binding Energy Values (kcal/mol)	Percent difference with current binding energy values (%)
3CL^{PRO} – Imatinib	-8.9 [12]	2.25%
3CL^{PRO} – Nilotinib	-9.2 [12]	3.26%
3CL^{PRO} – Dexamethasone	-7.4 [13]	1.35%

4. Conclusions

In this study, the molecular docking simulations were successfully conducted between the commercial drugs, Imatinib, Nilotinib and Dexamethasone were docked against 3CLPRO of the SARS-CoV-2 of coronavirus COVID-19 using the program Autodock Vina. Based on the results obtained, Nilotinib, Imatinib, and Dexamethasone might be a useful medication for treating COVID-19, but additional experimental tests are required to validate this.

References

1. Pascarella, G., A., Strumia., A., Piliego., C., E. "COVID-19 diagnosis and management: a comprehensive review." Journal of internal medicine, 2(282) (2020): 192- 206. DOI: https://doi.org/10.1111/joim.13091

2. Horby, P., W., Marfham., M., Bell., J., J. "Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial." The Lancet, 10259 (396)(2020): 1345-1352. DOI: https://doi.org/10.1016/S0140-6736(20)32013-4

3. Tang, B., Bragazzi., N., L., Q., Tang., J. "An updated estimation of the risk of transmission of the novel (2019-nCOV)." Infectious disease modelling, 5 (2020): 248-255. DOI: http://dx.doi.org/10.1016/j.idm.2020.02.001

4. Hui, David S., Esam I. Azhar, Tariq A. Madani, Francine Ntoumi, Richard Kock, Osman Dar, Giuseppe Ippolito et al. "The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China." *International journal of infectious diseases* 91 (2020): 264-266. DOI: https://doi.org/10.1016/j.ijid.2020.01.009

5. Huang, Chaolin, Yeming Wang, Xingwang Li, Lili Ren, Jianping Zhao, Yi Hu, Li Zhang et al. "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China." *The lancet* 395, no. 10223 (2020): 497-506. DOI: https://doi.org/10.1016/S0140-6736(20)30183-5

6. Klasse, P. J., and John P. Moore. "Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization." *Elife* 9 (2020): e57877. DOI: https://doi.org/10.7554/eLife.57877

7. Khan, Salman Ali, Komal Zia, Sajda Ashraf, Reaz Uddin, and Zaheer Ul-Haq. "Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach." *Journal of Biomolecular Structure and Dynamics* 39, no. 7 (2021): 2607-2616. DOI: https://doi.org/10.1080/07391102.2020.1751298

8. Zhou, Yonggang, Binqing Fu, Xiaohu Zheng, Dongsheng Wang, Changcheng Zhao, Yingjie Qi, Rui Sun, Zhigang Tian, Xiaoling Xu, and Haiming Wei. "Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients." *National Science Review* 7, no. 6 (2020): 998-1002. DOI: https://doi.org/10.1093/nsr/nwaa041

9. Muhammad Tahir ul Qamar, Safar M. Alqahtani, Mubarak A. Alamri, Ling-Ling Chen, Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants, Journal of Pharmaceutical Analysis, Volume 10, Issue 4, 2020, Pages 313-319, https://doi.org/10.1016/j.jpha.2020.03.009.

10. Mody, V., Ho, J., Wills, S. et al. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Commun Biol 4, 93 (2021). https://doi.org/10.1038/s42003-020-01577-x

11. Eberhardt, Jerome, Diogo Santos-Martins, Andreas Tillack, and Stefano Forli. "AutoDock Vina 1.2. 0: new docking methods, expanded force field, and Python bindings." (2021). DOI: https://doi.org/10.26434/chemrxiv.14774223.v1

12. Wallace, A. C., R. A. Laskowski, J. Singh, and J. M. Thornton. "Molecular recognition by proteins: protein-ligand interactions from a structural perspective." (1996): 280-284. DOI: 10.1042/bst0240280

13. Berman, Helen M., John Westbrook, Zukang Feng, Gary Gilliland, Talapady N. Bhat, Helge Weissig, Ilya N. Shindyalov, and Philip E. Bourne. "The protein data bank." *Nucleic acids research* 28, no. 1 (2000): 235-242. DOI: https://doi.org/10.1093/nar/28.1.235

14. Kim, Sunghwan, Paul A. Thiessen, Evan E. Bolton, Jie Chen, Gang Fu, Asta Gindulyte, Lianyi Han et al. "PubChem substance and compound databases." *Nucleic acids research* 44, no. D1 (2016): D1202-D1213. DOI: https://doi.org/10.1093/nar/gkv951

15. Molavi, Zahra, Sara Razi, Seyed Amir Mirmotalebisohi, Amirjafar Adibi, Marzieh Sameni, Farshid Karami, Vahid Niazi et al. "Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach." *Biomedicine & Pharmacotherapy* (2021): 111544. DOI: https://doi.org/10.1016/j.biopha.2021.111544

16. Kadela-Tomanek, Monika, Maria Jastrzębska, Krzysztof Marciniec, Ewa Bębenek, Elwira Chrobak, and Stanisław Boryczka. "Spectroscopic Investigations, Computational Analysis and Molecular Docking to SAR-Cov-2 Targets Studies of 5, 8-Quinolinedione Attached to Betulin Derivatives." *Crystals* 11, no. 1 (2021): 76. DOI: https://doi.org/10.3390/cryst11010076